Endocrine Abstracts

Introduction and objectives: Lenvatinib is the first line treatment for advanced radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC). Poorly differentiated thyroid carcinoma (PDTC) outcomes with Lenvatinib have only been subjected to sub analysis in one PHASE III study (SELECT), which might limit its real-world use in PDTC. We intend to compare the effectiveness of Lenvatinib in metastatic RAIR DTC and PDTC patients.Methods: Retrospectiv...

Introduction: Current imaging modalities for anaplastic thyroid cancer (ATC) have limited efficacy in evaluating remission and predicting recurrence due to residual disease. Circulating tumour DNA (ctDNA), isolated from liquid biopsies, could complement these methods and enhance diagnostic follow-up and disease monitoring. However, clinical follow-up studies using ctDNA in ATC remain scarce.Case report : An eighty-one-year-old woman with a history of HER...

Introduction and objectives: Anaplastic thyroid cancer (ATC) has a very low overall survival (OS) and progression free survival (PFS) due to fast growth and resistance to non-target therapies. A recent phase II study showed a dramatic increase in OS and PFS of BRAF V600E mutated ATC patients treated with Dabrafenib and Trametinib (DT). However as commonly reported in melanoma durable responses in ATC may be compromised by resistance mechanisms. Until now only a few ca...